CY1105684T1 - Ανοσοενισχυτικα εμβολιων - Google Patents

Ανοσοενισχυτικα εμβολιων

Info

Publication number
CY1105684T1
CY1105684T1 CY20061100288T CY061100288T CY1105684T1 CY 1105684 T1 CY1105684 T1 CY 1105684T1 CY 20061100288 T CY20061100288 T CY 20061100288T CY 061100288 T CY061100288 T CY 061100288T CY 1105684 T1 CY1105684 T1 CY 1105684T1
Authority
CY
Cyprus
Prior art keywords
immune boosters
vaccines immune
adjuvants
vaccines
oil
Prior art date
Application number
CY20061100288T
Other languages
English (en)
Inventor
Don Alan Dearwester
Leroy Allen Swearingin
David Stewart Roberts
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of CY1105684T1 publication Critical patent/CY1105684T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση σχετίζεται με ανοσοενισχυτικά μίας λεκιθίνης, ενός ελαίου και ενός αμφιπαθητικού επιφανειοδραστικού παράγοντα τα οποία ανοσοενισχυτικά είναι ικανά να σχηματίσουν ένα εμβόλιο ευσταθούς γαλακτώματος ελαίου σε ύδωρ ούτως ώστε να ελαχιστοποιούνται οι τοπικές αντιδράσεις κατόπιν εμβολιασμού ζώου.
CY20061100288T 1999-01-29 2006-03-01 Ανοσοενισχυτικα εμβολιων CY1105684T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11770599P 1999-01-29 1999-01-29
US12176099P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
CY1105684T1 true CY1105684T1 (el) 2010-12-22

Family

ID=26815550

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061100288T CY1105684T1 (el) 1999-01-29 2006-03-01 Ανοσοενισχυτικα εμβολιων
CY20111101249T CY1112521T1 (el) 1999-01-29 2011-12-16 Bordetella bronchiseptica εμβολιο

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111101249T CY1112521T1 (el) 1999-01-29 2011-12-16 Bordetella bronchiseptica εμβολιο

Country Status (17)

Country Link
US (6) US6572861B1 (el)
EP (2) EP1023904B1 (el)
JP (3) JP2000219636A (el)
CN (2) CN1126568C (el)
AR (2) AR035474A1 (el)
AT (2) ATE533504T1 (el)
AU (2) AU769539B2 (el)
BR (2) BRPI0000126B8 (el)
CA (2) CA2296244C (el)
CY (2) CY1105684T1 (el)
DE (1) DE69928763T2 (el)
DK (2) DK1023904T3 (el)
ES (2) ES2374628T3 (el)
HK (2) HK1030166A1 (el)
NZ (2) NZ502341A (el)
PT (1) PT1616573E (el)
TW (1) TW585777B (el)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7279163B1 (en) * 2002-03-21 2007-10-09 The United States Of America, As Represented By The Secretary Of Agriculture Water-in-oil emulsion vaccines
OA12915A (en) * 2002-08-26 2006-10-13 Pfizer Prod Inc Vaccine for respiratory and reproductive system infections in cattle.
CA2513352C (en) 2003-01-29 2010-10-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
WO2004087204A2 (en) * 2003-04-04 2004-10-14 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
US8637047B2 (en) * 2003-10-30 2014-01-28 Boehringer Ingelheim Vetmedica, Inc. Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
CN1323718C (zh) * 2004-03-15 2007-07-04 中国农业科学院兰州兽医研究所 一种利用植物油佐剂制备动物病毒性、细菌性疫苗的方法
FR2878746B1 (fr) * 2004-12-02 2007-02-23 Vetoquinol Sa Sa Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins
CN1320924C (zh) * 2005-01-07 2007-06-13 邢为藩 一种自乳化疫苗佐剂及其制备方法
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007317347B2 (en) * 2006-11-03 2014-02-06 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
NZ602945A (en) 2008-06-27 2014-05-30 Zoetis Llc Novel adjuvant compositions
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
KR20170102039A (ko) 2009-04-03 2017-09-06 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
US9849174B2 (en) 2009-11-20 2017-12-26 The Board Of Regents Of The University Of Texas System Methods and compositions related to immunogenic fibrils
US9241987B2 (en) 2009-11-20 2016-01-26 The University Of Chicago Methods and compositions related to immunogenic fibrils
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
JP2013522231A (ja) 2010-03-11 2013-06-13 イミューン デザイン コーポレイション インフルエンザのためのワクチン
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
WO2011134669A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
EP2563404B1 (en) 2010-04-30 2016-09-21 Urogen Pharma Ltd. Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
WO2012034067A1 (en) 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
GB201205237D0 (en) 2012-03-26 2012-05-09 Univ Edinburgh Adjuvant
NZ702285A (en) 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
HUE059179T2 (hu) 2012-09-10 2022-10-28 Galenbio Inc Vízimadárban Mycoplasma-fertõzés megelõzésére szolgáló oltóanyag
CA2881863A1 (en) 2012-10-01 2014-04-10 Telormedix Sa Phospholipid drug analogs
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2016007576A2 (en) 2014-07-11 2016-01-14 Zoetis Services Llc Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
JP6824177B2 (ja) 2015-02-27 2021-02-03 アイオア・ステート・ユニバーシティー・リサーチ・ファンデーション・インコーポレーテッドＩｏｗａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ Ｉｎｃｏｒｐｏｒａｔｅｄ 豚流行性下痢ウイルス株及びそれから得られる免疫原性組成物
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
BR112018069371A2 (pt) 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN107027749B (zh) * 2017-05-24 2021-04-09 浙江工业大学 一种复合乳化剂及其在复配毒死蜱农药中的应用
ES2705378A1 (es) * 2017-09-22 2019-03-22 Decco Worldwide Post Harvest Holdings B V Metodo para el tratamiento y control de fisiopatias de postcosecha de frutas mediante recubrimientos comestibles.
US11413336B2 (en) 2018-03-23 2022-08-16 Board Of Regents, The University Of Texas System Coccidioides antigens and methods of their use
EP3843782A1 (en) 2018-08-29 2021-07-07 Centre Hospitalier Universitaire Vaudois (CHUV) Ebola vaccine compositions and methods of using same
US11208167B2 (en) 2018-11-15 2021-12-28 Kuat Innovations Llc Bicycle rack with actuated arm
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
CN113907044A (zh) * 2021-11-09 2022-01-11 福建省连江县刘氏兔业养殖场 一种抗病猪品系的培育方法及其应用
WO2023111907A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
AT350181B (de) * 1977-05-04 1979-05-10 Schuller Walter Dr Verfahren zur herstellung einer mischvaccine
US4137115A (en) * 1977-11-07 1979-01-30 Patrick Lambert Joining structure
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4261925A (en) 1978-04-05 1981-04-14 The Dow Chemical Company Surfactants
US4504275A (en) 1983-03-24 1985-03-12 Imperial Chemical Industries Plc Emulsifying agents
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US5424323A (en) * 1985-01-18 1995-06-13 Cetylite Industries, Inc. Sterilant composition
US5338748A (en) 1985-01-18 1994-08-16 Cetylite Industries, Inc. Sterilant composition
DE3517805A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Impfstoff zur immunisierung von schweinen gegen rhinitis atrophicans (schnueffelkrankheit)
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5209929A (en) * 1987-03-19 1993-05-11 Washington State University Research Foundation Immunization against Babesiosis using purified merozoite surface antigens of Basesia bigemina
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5069901A (en) * 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
DE69113991T2 (de) * 1990-02-12 1996-03-21 Smithkline Beecham Biologicals S.A., Rixensart Impfstoff.
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
JP3187419B2 (ja) * 1990-05-29 2001-07-11 アメリカン・サイアナミド・カンパニー ブタ肺炎ワクチンおよびその製造方法
ATE183202T1 (de) 1990-06-13 1999-08-15 Pfizer Pasteurella multocida toxoid enthaltende impfstoffe
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
CA2123222C (en) 1991-11-15 2001-02-27 Donald A. Dearwester Gram-negative bacterial vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
DE4222153C2 (de) 1992-07-06 1998-12-03 Peter Siegfried Verfahren zur Entölung von Rohlecithin
EP0626452B1 (en) * 1993-05-17 1999-08-11 Akzo Nobel N.V. Vaccine against Streptococcus suis infection
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2183867T3 (es) 1994-02-18 2003-04-01 Solidose L L C Inoculacion de animales con materiales biologicos secados en peletes.
GB2289279B (en) * 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
JP3884066B2 (ja) * 1994-06-10 2007-02-21 財団法人化学及血清療法研究所 ボルデテラ属菌産生壊死毒素の精製方法およびトキソイド
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5625038A (en) * 1994-07-27 1997-04-29 Henderson; Louise M. Monoclonal antibodies specific for Erysipelothrix rhusiopathiae
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5814321A (en) 1995-11-30 1998-09-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
DK0835930T3 (da) 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
ZA982870B (en) * 1997-04-10 1998-10-09 Akzo Nobel Nv Live attenuated bacteria of the species actinobacillus pleuropneumoniae
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae

Also Published As

Publication number Publication date
NZ513202A (en) 2003-02-28
US6572861B1 (en) 2003-06-03
DK1023904T3 (da) 2005-12-27
JP2000219636A (ja) 2000-08-08
BRPI0000126B1 (pt) 2015-07-14
CN1449825B (zh) 2012-08-22
JP4785365B2 (ja) 2011-10-05
CA2296244C (en) 2004-04-27
DK1616573T3 (da) 2012-01-30
ES2374628T3 (es) 2012-02-20
ES2251164T3 (es) 2006-04-16
PT1616573E (pt) 2012-01-11
US20030175309A1 (en) 2003-09-18
EP1616573B1 (en) 2011-11-16
TW585777B (en) 2004-05-01
AU6537299A (en) 2000-08-03
US20050058667A1 (en) 2005-03-17
ATE533504T1 (de) 2011-12-15
BR0000126A (pt) 2001-05-02
NZ502341A (en) 2001-08-31
US20030175308A1 (en) 2003-09-18
CN1270838A (zh) 2000-10-25
BRPI0000126B8 (pt) 2022-05-10
CA2455134C (en) 2010-05-11
CA2455134A1 (en) 2000-07-29
DE69928763D1 (de) 2006-01-12
JP5167469B2 (ja) 2013-03-21
EP1616573A3 (en) 2007-05-09
BRPI0017566B1 (pt) 2015-11-10
CN1126568C (zh) 2003-11-05
EP1023904A2 (en) 2000-08-02
EP1023904A3 (en) 2002-08-21
US20030175298A1 (en) 2003-09-18
US20030175299A1 (en) 2003-09-18
EP1616573A2 (en) 2006-01-18
ATE311900T1 (de) 2005-12-15
EP1023904B1 (en) 2005-12-07
CA2296244A1 (en) 2000-07-29
AR035474A1 (es) 2004-06-02
CY1112521T1 (el) 2015-12-09
US7393535B2 (en) 2008-07-01
HK1030166A1 (en) 2001-04-27
US6733754B2 (en) 2004-05-11
AU769539B2 (en) 2004-01-29
AR055422A2 (es) 2007-08-22
JP2004002479A (ja) 2004-01-08
HK1059739A1 (en) 2004-07-16
DE69928763T2 (de) 2006-06-29
CN1449825A (zh) 2003-10-22
AU2004201021A1 (en) 2004-04-08
JP2005041883A (ja) 2005-02-17
US6814971B2 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
CY1105684T1 (el) Ανοσοενισχυτικα εμβολιων
CY1114333T1 (el) Αντιγονα του neisseria meningitidis
CY1106103T1 (el) Μεθοδος διαχωρισμου παραλλαγων ροταϊου και ζωντανο εξασθενημενο εμβολιο ροταϊου
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
UY27945A1 (es) Acidos nucleicos inmunoestimuladores
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
TR200200774T2 (tr) Aşılar.
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
CY1113826T1 (el) Ανοσοενισχυτικα για εμβολια
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
TW200509966A (en) Microfluidized oil-in-water emulsions and vaccine compositions
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
PT1003548E (pt) Dispositivo para a inducao de uma resposta por ctl
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
DE60044146D1 (de) D ihre verwendungen
CY1108526T1 (el) Εμβολια εναντι καρκινων
DE69739385D1 (de) Verbesserte impfstoffe
HUP9701586A2 (hu) Javított inaktivált vakcinák
ATE292674T1 (de) Neue antigenklasse von geflügelreoviren
HUP9801572A2 (hu) Chlamydia-vakcinák